View:
Download DOC
Download PDF
Download XLS

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

____________

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act Of 1934

 

December 10, 2015

Date of Report (Date of earliest event reported)

___________________________________________________________

 

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

___________________________________________________________

 

 

State of New York 1-10113 11-0853640
(State of Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation)   Identification Number)

 

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

 

(847) 705-7709

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

 

 

 

 

 

Item 5.02Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(e)

 

On December 10, 2015 we awarded cash bonuses to, and effective January 1, 2016, increased the annual salaries of, the named executive officers listed below, in the amounts provided:

 

 

Name Title Annual Salary Bonus Award
Robert B. Jones President and Chief Executive Officer $393,000 (increased
from $392,000)		 $215,600
Peter A. Clemens Senior Vice President and Chief Financial Officer $286,000 (increased
from $285,000)		 $109,700
Albert W. Brzeczko Vice President, Technical Affairs of Acura Pharmaceutical Technologies, Inc. $291,000 (increased
from $290,000)		 $68,500
Robert A. Seiser Vice President, Controller and Treasurer $175,500 (increased
from $175,000)		 $35,200
James F. Emigh Vice President, Corporate Development $175,500 (increased
from $175,000)		 $21,400
J. Bradley Rivet Vice President, Marketing $175,500 (increased
from $175,000)		 $30,600

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ACURA PHARMACEUTICALS, INC.
   
  By:  /s/ Peter A. Clemens
    Peter A. Clemens
Senior Vice President & Chief Financial Officer

 

Date: December 16, 2015